



**PHARMACEUTICALS EXPORT PROMOTION COUNCIL**

(Set up by Ministry of Commerce, Govt. of India)

**COPY**

**Date : 02-06-2010**

**News / Story reproduced with thanks:- Economic Times**

**Aurobindo's net for FY 10 jumps to Rs 563 cr**

Direct link to the News/Story:-

<http://economictimes.indiatimes.com/articleshow/5989471.cms?prtpage=1>

HYDERABAD: Aurobindo Pharma's net profit for the financial year ended on March 31 has jumped over five times to Rs 563.4 crore as against Rs 100.26 crore in the last year.

Revenues of the company stood at Rs 3575.43 crore as against Rs 3077.29 crore in the last fiscal. Revenues from the formulations, which contributed 53.6 per cent to the overall revenues, was up by 32.6 per cent to 1852.1 crore, the company said.

The company's sales from the USA nearly doubled to Rs 912.4 crore from Rs 536.8 crore last year while sales from Europe stood at 237.2 over last year's 197.6 crore.

According to Sudhir Sanghvi, Chief Financial Officer of the company, an improvement in Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and advantage in raw material costs pushed the profits up.

"The deal with Pfizer also contributed \$47 to 50 million this year. Next year it would be significant," Sanghvi told PTI.

Last year, Pharma Giant Pfizer entered into an agreement with Aurobindo to sell generic drugs made by the later in the US and Europe markets.

Sanghvi said as on March 31, as many as 113 ANDAs (Abbreviated New Drug Application) have been approved in USA including 29 tentative approvals. The Company has so far launched 61 products in the USA market.